Pathogenic lipid-binding antiphospholipid antibodies are associated with severity of COVID-19.

ABSTRACT:

Background

Coronavirus disease 19 (COVID-19)-associated coagulopathy is a hallmark of disease severity and poor prognosis. The key manifestations of this prothrombotic syndrome-microvascular thrombosis, stroke, and venous and pulmonary clots-are also observed in severe and catastrophic antiphospholipid syndrome. Antiphospholipid antibodies (aPL) are detectable in COVID-19 patients, but their association with the clinical course of COVID-19 remains unproven.

Objectives

To analyze the presence and relevance of lipid-binding aPL in hospitalized COVID-19 patients.

Methods

Two cohorts of 53 and 121 patients from a single center hospitalized for PCR-proven severe acute respiratory syndrome-coronavirus 2 infection were analyzed for the presence of aPL and clinical severity o

SUBMITTER: Hollerbach A 

PROVIDER: S-EPMC8420426 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature